Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab)

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 4, 2003, Pages 351-354

  Garcia Planella, Esther ^a   Domènech, Eugeni ^a   Esteve Comas, Maria ^b   Bernal, Isabel ^a   Cabré, Eduard ^a   Boix, Jaume ^a   Gassull, Miquel A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Antinuclear antibodies; Crohn's disease; Infliximab

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LUPUS ERYTHEMATOSUS; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CHILD; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED;

EID: 0242499967     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200304000-00003     Document Type: Article

References (13)

1. Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337:1029-1035.
2. Rutgeerts P, D'Haens GD, Targan S, Vasiliaukas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117:761-769.
3. Present DH, Rutgeerts P, Targan S, Mayer L, van Hogezand RA, Podolsky DK, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
4. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflam Bowel Dis 1999; 5:119-133.
5. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95:3469-3477.
6. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95:3490-3497.
7. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96:722-729.
8. Zauli D, Crespi C, Dall'Amore P, Bianchi FB, Pisi E. Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease. Digestion 1985; 32:140-144.
9. Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM. Soluble interleukin-2 receptors anti-neutrophil cytoplasmatic antibodies and other autoantibodies in patients with ulcerative colitis. Gut 1993; 34:658-664.
10. Reumaux D, Meziere C, Colombel JF, Duthilleul P, Mueller S. Distinct production of autoantibodies to nuclear components in ulcerative colitis and Crohn's disease. Clin Immunol Immunopathol 1995; 77:349-357.
11. Folwaczny C, Noehl N, Endres SP, Heldwein W, Loeschke K, Fricke H. Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig Dis Sci 1997; 42:1593-1597.
12. Remicade™ (infliximab). Prescribing information. Centocor, Inc., Malvern, PA, August 1998.
13. Vermeire S, Noman M, Van Assche G, Esters N, Joossens S, Baert F, et al. Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation. Gastroenterology 2001; 120:A69.